Drug Discovery Today

Drug Discovery Today is a peer-reviewed review journal published by Elsevier since 1996 under the ISSN 1359-6446 and eISSN 1878-5832, covering drug discovery and development across the pharmaceutical pipeline, with a 2025 Journal Impact Factor of 8.7 and a first quartile rank of 17 of 356 in pharmacology and pharmacy《今日药物发现》（Drug Discovery Today）是爱思唯尔（Elsevier）自 1996 年起出版的同行评审综述期刊，刊号 1359-6446、电子刊号 1878-5832，覆盖药物发现与研发全流程，2025 年影响因子为 8.7，在药理学与药剂学类 356 种期刊中列第 17 位、居第一四分位。

Scope

• The journal publishes reviews, perspectives and news articles on drug discovery and development, covering target identification, lead discovery, preclinical studies and translational research该刊刊载药物发现与研发领域的综述、观点与新闻文章，覆盖靶点识别、先导化合物发现、临床前研究与转化研究。
• Topics include computational and structural biology, high-throughput screening, medicinal chemistry, pharmacokinetics and pharmacodynamics, drug safety and biomarkers主题涵盖计算与结构生物学、高通量筛选、药物化学、药代动力学与药效学、药物安全性与生物标志物。
• The journal also covers emerging modalities such as biologics, nucleic acid therapeutics, cell and gene therapies, and drug delivery technologies该刊还覆盖生物制品、核酸治疗、细胞与基因治疗以及药物递送技术等新兴模式。
• Article types include reviews, perspectives, keynote reviews, news and features, and the journal operates a monthly publication schedule文章类型包括综述、观点、主题综述、新闻与专题，该刊采用月刊出版节奏。
• As a hybrid journal it offers subscription access alongside optional open access, with open access articles released under a Creative Commons licence作为混合期刊，该刊提供订阅访问与可选开放获取，开放获取文章采用知识共享许可发布。
• It is abstracted and indexed in the Science Citation Index Expanded, Scopus, PubMed, MEDLINE and Embase, and it is included in the Journal Citation Reports from the Science Citation Index Expanded edition该刊被（SCIE）、（Scopus）、（PubMed）、（MEDLINE）与（Embase）收录，并纳入（SCIE）版期刊引证报告。

History

• The journal was launched in 1996 by Elsevier as a review-led title for the drug discovery community, with the first volume appearing in the same year该刊于 1996 年由爱思唯尔创办，定位为面向药物发现群体的综述型期刊，首卷同年出版。
• Elsevier later expanded the brand with companion titles covering technologies, disease models, therapeutic strategies and new drug targets, while the main journal retained the broad discovery scope爱思唯尔随后扩展该品牌，推出覆盖技术、疾病模型、治疗策略与新药靶点的姊妹刊，主刊则保留广泛的发现范围。
• The Journal Impact Factor moved from 7.851 in 2021 to 8.369 in 2022, then to 7.5 in 2024 and 8.7 in 2025, maintaining first quartile standing in pharmacology and pharmacy该刊影响因子由 2021 年的 7.851 升至 2022 年的 8.369，2024 年为 7.5，2025 年升至 8.7，始终居药理学与药剂学类第一四分位。
• The journal has progressively expanded its coverage of emerging therapeutic modalities, introducing dedicated content on cell and gene therapies and nucleic acid therapeutics in recent years该刊逐步扩展对新兴治疗模式的覆盖，近年引入细胞与基因治疗及核酸治疗方向的专题内容。
• The publisher carries the journal on the ScienceDirect platform and the digital object identifier prefix of its articles is 10.1016, shared with other Elsevier titles出版方将该刊载于科学直通平台，其文章的数字对象唯一标识符前缀为（10.1016），与爱思唯尔其他期刊一致。

Editors

• The journal is led by an editor-in-chief supported by a senior editorial board and an international advisory board whose members are drawn from pharmaceutical companies, biotechnology firms and academic research centres该刊由一位主编带领，配以资深编委会与由制药企业、生物技术公司与学术研究中心学者组成的国际顾问委员会。
• The editorial board includes section editors responsible for subject areas such as medicinal chemistry, pharmacokinetics, drug safety and emerging therapeutics, reflecting the pipeline scope of the journal编委会设有领域编辑，分别负责药物化学、药代动力学、药物安全性与新兴治疗等方向，对应刊物的研发流程定位。
• Editorial handling follows the Elsevier editorial management system, with submissions assigned to handling editors based on subject expertise and competing interest declarations稿件处理依托爱思唯尔的编辑管理系统，依据学科专长与利益冲突声明分配责任编辑。
• Peer review is single-blind and the journal maintains the Elsevier standards on reviewer recruitment, conflict of interest management, data sharing and editorial independence同行评审采用单盲方式，该刊遵循爱思唯尔在审稿人遴选、利益冲突管理、数据共享与编辑独立性方面的标准。
• The masthead and board roster are published on the journal page at ScienceDirect and updated as new members join or existing members step down编委名单在科学直通期刊页公布，并随成员增减而更新。